Barbosa Rafaela Miranda, Obata Malu Mateus Santos, Neto José Rodrigues do Carmo, Guerra Rhanoica Oliveira, Borges Anna Victória Bernardes E, Trevisan Rafael Obata, Ruiz Letícia Cirelli, Bernardi Júlia de Moura, Oliveira-Scussel Ana Carolina de Morais, Vaz Tanaka Sarah Cristina Sato, de Vito Fernanda Bernadelli, Helmo Fernanda Rodrigues, de Assunção Thaís Soares Farnesi, Machado Juliana Reis, de Oliveira Carlo José Freire, Júnior Virmondes Rodrigues, Silva Anielle Christine Almeida, da Silva Marcos Vinicius
Department of Microbiology, Immunology and Parasitology, Institute of Biological and Natural Sciences, Federal University of Triângulo Mineiro, Uberaba 38025-180, Minas Gerais, Brazil.
Department of Bioscience and Technology, Institute of Tropical Pathology and Public Health, Federal University of Goias, Goiania 74690-900, Goiás, Brazil.
Pharmaceutics. 2022 Nov 29;14(12):2642. doi: 10.3390/pharmaceutics14122642.
Tegumentary leishmaniasis (TL) is caused by parasites of the genus Leishmania. () is one of the most clinically relevant pathogens that affects the skin and mucosa, causing single or multiple disfiguring and life-threatening injuries. Even so, the few treatment options for patients have significant toxicity, high dropout rates, high cost, and the emergence of resistant strains, which implies the need for studies to promote new and better treatments to combat the disease. Zinc oxide nanocrystals are microbicidal and immunomodulatory agents. Here, we develop new Ag-ZnO/xAgO nanocomposites (NCPs) with three different percentages of silver oxide (AgO) nanocrystals (x = 49%, 65%, and 68%) that could act as an option for tegumentary leishmaniasis treatment. Our findings showed that 65% and 68% of AgO inhibit the extra and intracellular replication of and present a high selectivity index. Ag-ZnO/65%AgO NCPs modulate activation, expression of surface receptors, and cytokine production by human peripheral blood mononuclear cells toward a proinflammatory phenotype. These results point to new Ag-ZnO/AgO nanocomposites as a promising option for treatment.
皮肤利什曼病（TL）由利什曼原虫属的寄生虫引起。它是影响皮肤和黏膜的最具临床相关性的病原体之一，会导致单个或多个毁容性且危及生命的损伤。即便如此，针对患者的治疗选择很少，且具有显著毒性、高停药率、高成本以及耐药菌株的出现，这意味着需要开展研究以推动新的更好的治疗方法来对抗该疾病。氧化锌纳米晶体是具有杀菌和免疫调节作用的药剂。在此，我们开发了具有三种不同百分比氧化银（AgO）纳米晶体（x = 49%、65%和68%）的新型Ag-ZnO/xAgO纳米复合材料（NCPs），它们可作为皮肤利什曼病治疗的一种选择。我们的研究结果表明，65%和68%的AgO可抑制利什曼原虫的胞外和胞内复制，并呈现出高选择性指数。Ag-ZnO/65%AgO NCPs可调节人外周血单核细胞的活化、表面受体表达以及细胞因子产生，使其朝着促炎表型发展。这些结果表明新型Ag-ZnO/AgO纳米复合材料是治疗皮肤利什曼病的一个有前景的选择。
